Parallel Advisors LLC Has $340,000 Stake in United Therapeutics Corporation $UTHR

Parallel Advisors LLC lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 18.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,184 shares of the biotechnology company’s stock after purchasing an additional 185 shares during the period. Parallel Advisors LLC’s holdings in United Therapeutics were worth $340,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. XTX Topco Ltd acquired a new position in United Therapeutics in the first quarter valued at approximately $313,000. Allianz Asset Management GmbH lifted its holdings in United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after buying an additional 33,254 shares during the period. LPL Financial LLC lifted its holdings in United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after buying an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after buying an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new stake in United Therapeutics in the first quarter worth $227,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of UTHR stock opened at $417.57 on Friday. The stock has a market cap of $18.84 billion, a P/E ratio of 16.30, a P/E/G ratio of 6.37 and a beta of 0.62. The company has a fifty day moving average price of $329.55 and a two-hundred day moving average price of $310.67. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $436.95.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.85 EPS. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on UTHR. Jefferies Financial Group increased their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Morgan Stanley cut their target price on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Cantor Fitzgerald increased their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Oppenheimer increased their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $438.85.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $400.17, for a total transaction of $1,600,680.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $52,022.10. This trade represents a 96.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $406.17, for a total transaction of $4,467,870.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $14,939,338.77. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 172,116 shares of company stock worth $63,256,557 in the last quarter. 10.30% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.